Dyne (DYN) news

RBC raises target price to $35 from $30 for Dyne Therapeutics, Inc

RBC Capital Markets has revised its target price for Dyne Therapeutics, Inc. (NASDAQ: DYN), increasing it from $30 to $35, reflecting a more optimistic outlook on the company’s near-term prospects [1]. The adjustment follows recent developments in the company’s clinical pipeline and improved market…

Dyne Therapeutics prices of upsized offering at $20.50/share

Dyne Therapeutics, Inc. (Nasdaq: DYN) has priced an upsized public offering of 18,980,478 shares of its common stock at $18.44 per share, raising gross proceeds of $350.0 million before underwriting discounts and offering expenses. The offering, which closed on December 11, 2025, included the full…

Dyne Therapeutics prices upsized $375M offering of stock

Dyne Therapeutics, Inc. (Nasdaq: DYN) has priced an upsized public offering of 21,827,549 shares of its common stock at $18.44 per share, raising gross proceeds of approximately $402.5 million before underwriting discounts and offering expenses. The offering includes full exercise of underwriters'…

Dyne Therapeutics said to offer shares at up to 16% discount

Dyne Therapeutics, Inc. (Nasdaq: DYN) recently completed a public offering of 27,878,788 shares of its common stock at a public offering price of $8.25 per share, representing a 16% discount compared to its initial public offering price of $19.00 per share in September 2020. The offering included…

Dyne Therapeutics said to offer shares for $20-$21.50 each